Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies

Brain

Volumn 123, Issue 4, 2000, Pages 710-717

  Nobile Orazio, E ^a,b   Meucci, N ^a   Baldini, L ^a   Di Troia, A ^a   Scarlato, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

IgM monoclonal gammopathy; Myelin associated glycoprotein; Neuropathy; Prognosis; Therapy

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; MELPHALAN; MYELIN ASSOCIATED GLYCOPROTEIN; PREDNISONE; STEROID;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ATAXIA; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; FOLLOW UP; HEPATITIS; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNOTHERAPY; LEUKEMIA; LUNG EDEMA; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR;

EID: 0034065240     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.4.710     Document Type: Article

References (43)

1. Aymard JP, Witz F, Conroy T, Lederlin P, Humbert JC, Barroche G, et al. Leucémie aiguë secondaire au traitement de la sclèrose en plaque par le chlorambucil. Rev Neurol (Paris) 1985; 141: 152-4.
2. Baldini L, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenström macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol 1994; 45: 25-31.
3. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995; 45: 1577-80.
4. Chassande B, Léger JM, Ben Younes-Chennoufi A, Bengoufa D, Maisonobe T, Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998; 21: 55-62.
5. Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990; 40: 212-4.
6. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996; 40: 792-5.
7. Ernerudh J, Brodtkorb E, Olsson T, Vedeler CA, Nyland H, Berlin G. Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange. J Neuroimmunol 1986; 11: 171-8.
8. Ernerudh JH, Vrethem M, Andersen O, Lindberg C, Berlin G. Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. J Neurol Neurosurg Psychiatry 1992; 55: 930-4.
9. Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 8th edn. New York: Pergamon Press; 1990.
10. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann Neurol 1988; 23: 394-6.
11. Hays AP, Latov N, Takatsu M, Sherman WH. Experimental demyelination of nerve induced by serum of patients with neuropathy and anti-MAG IgM M-protein. Neurology 1987; 37: 242-56.
12. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 1988; 18: 231-44.
13. Hoang-Xuan K, Leger JM, Ben Younes-Chennoufi A, Saidi H, Bouche P, Baumann N, et al. Traitement des neuropathies dysimmunitaires par immunoglobulines polyvalentes intraveineuses. Rev Neurol (Paris) 1993; 149: 385-92.
14. Kelly JJ, Adelman LS, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 1988; 45: 1355-9.
15. Latov N, Sherman WH, Nemni R, Galassi G, Shyong JS, Penn AS, et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med 1980; 303: 618-21.
16. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. [Review]. Crit Rev Neurobiol 1988; 3: 301-32.
17. Latov N, Sherman WH, Vlahides G. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan [abstract]. Neurology 1999; 52 Suppl 2: A551.
18. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999; 52: 1701-4.
19. Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC. A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997; 63: 28-34.
20. Meier C, Roberts K, Steck A, Hess C, Miloni E, Tschopp L. Polyneuropathy in Waldenström's macroglobulinaemia: reduction of endoneurial IgM-deposits after treatment with chlorambucil and plasmapheresis. Acta Neuropathol (Berl) 1984; 64: 297-307.
21. Melmed C, Frail D, Duncan I, Braun P, Danoff D, Finlayson M, et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 1983; 33: 1397-405.
22. Meucci N, Baldini L, Cappellari A, Di Troia A, Allaria S, Scarlato G, et al. Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann Neurol 1999; 46: 119-22.
23. Monaco S, Bonetti B, Ferrari S, Moretto G, Nardelli E, Tedesco F, et al. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med 1990; 322: 649-52.
24. Monaco S , Ferrari S, Bonetti B, Moretto G, Kirshfink M, Nardelli E, et al. Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol 1995; 54: 96-104.
25. Nemni R, Galassi G, Latov N. Sherman WH, Olarte MR, Hays AP. Polyneuropathy in nonmalignant IgM plasma cell dyscrasia: a morphological study. Ann Neurol 1983; 14: 43-54.
26. Nobile-Orazio E. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JH, Kelly JJ, editors. Immunology and infectious diseases of the peripheral nerves. Cambridge: Cambridge University Press; 1998. p. 168-89.
27. Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987; 37: 1506-14.
28. Nobile-Orazio E, Baldini L, Barbieri S, Marmiroli P, Spagnol G, Francomano E, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 1988; 24: 93-7.
29. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993; 43: 537-44.
30. Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36: 416-24.
31. Notermans NC, Wokke JH, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FG. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994; 117: 1385-93.
32. Notermans NC, Lokhorst HM, Franssen H, Van der Graaf Y, Teunissen LL, Jennekens FG, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996; 47: 1227-33.
33. Notermans NC, Vermeulen M, Lokhorst HM, Van Doorn PA, Van den Berg LH, Teunissen LL, et al. Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy [letter]. J Neurol 1997; 244: 462-3.
34. Oksenhendler E, Chevret S, Léger J-M, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 1995; 59: 243-7.
35. Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D. Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment. Neurology 1998; 51: 1210-3.
36. Sherman WH, Latov N, Lange D, Hays R, Younger D. Fludarabine for IgM antibody-mediated neuropathies [abstract]. Ann Neurol 1994; 36: 326-7.
37. Smith IS. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain 1994; 117: 949-57.
38. Smith T, Sherman W, Olarte MR, Lovelace RE. Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow-up study. Acta Neurol Scand 1987; 75: 244-8.
39. Stefansson K, Marton L, Antel JP, Wollmann RL, Roos RP, Chejfec G, et al. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathol (Berl) 1983; 59: 255-61.
40. Tatum AH. Experimental paraprotein neuropathy; demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol 1993; 33: 502-6.
41. Van den Berg L, Hays AP, Nobile-Orazio E, Kinsella LJ, Manfredini E, Corbo M, et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996; 19: 637-43.
42. Vital A, Vital C, Julien J, Baquey A, Steck AJ. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol (Berl) 1989; 79: 160-7.
43. Wilson HC, Lunn MPT, Schey S, Hughes RAC. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999; 66: 575-80.